Losmapimod oral tablet + Placebo oral tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Timeline
Aug 9, 2019 → Jan 28, 2021
NCT ID
NCT04003974About Losmapimod oral tablet + Placebo oral tablet
Losmapimod oral tablet + Placebo oral tablet is a phase 2 stage product being developed by Fulcrum Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is completed. This product is registered under clinical trial identifier NCT04003974. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04511819 | Phase 3 | Terminated |
| NCT04003974 | Phase 2 | Completed |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 52 |
| ACE-083 | Merck | Phase 2 | 52 |
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 74 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |